Abstract
Summary
Cerebrovascular diseases are a group of condition characterized by a certain dysfunction of blood vessels supplying the brain and also affect the flow of blood in an individual’s brain. For proper functioning of the brain, it needs certain nutrients and oxygen from the arteries. However, if there is any kind of restriction in the blood flow, the brain cells begin to die. The prime causes of cerebrovascular disease are cerebral thrombosis, cerebral embolism, and cerebral hemorrhage. Due to cerebrovascular disease, part of the brain is affected due to bleeding and thereby leads to different types of cerebrovascular diseases such as stroke, transient ischaemic attack (TIA), vascular dementia, and subarachnoid hemorrhage.
LPI (LP Information)' newest research report, the “Cerebrovascular Disease Industry Forecast” looks at past sales and reviews total world Cerebrovascular Disease sales in 2024, providing a comprehensive analysis by region and market sector of projected Cerebrovascular Disease sales for 2025 through 2031. With Cerebrovascular Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cerebrovascular Disease industry.
This Insight Report provides a comprehensive analysis of the global Cerebrovascular Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cerebrovascular Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cerebrovascular Disease market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cerebrovascular Disease and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cerebrovascular Disease.
The global Cerebrovascular Disease market size is projected to grow from US$ million in 2024 to US$ million in 2031; it is expected to grow at a CAGR of % from 2025 to 2031.
According to Centers for Disease Control and Prevention, cerebrovascular disease is the fourth most common cause of death in the U.S. Following North America, European countries are also expected to show steady growth in the market. In the next few years, Asia-Pacific would show remarkable growth in the cerebrovascular disease market as it is developing at a very rapid pace. The factors which would fuel the growth of the market in Asia Pacific are increasing awareness about cerebrovascular disease, certain family history related to the disease and rapidly developing technologically advanced treatments.
This report presents a comprehensive overview, market shares, and growth opportunities of Cerebrovascular Disease market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Carotid Endarterectomy
Carotid Angioplasty Or Carotid Artery Stenting
Drug Medication (Aspirin, Ticlopidine, And Sulfinpyrazone)
Segmentation by application
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Hospitals & Diagnostic Centers
Contract Research Organizations
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Johnson & Johnson
Amgen
GlaxoSmithKline
Sanofi-Aventis
Merck
Sangamo BioSciences
Aldagen
LPI (LP Information)' newest research report, the “Cerebrovascular Disease Industry Forecast” looks at past sales and reviews total world Cerebrovascular Disease sales in 2024, providing a comprehensive analysis by region and market sector of projected Cerebrovascular Disease sales for 2025 through 2031. With Cerebrovascular Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cerebrovascular Disease industry.
This Insight Report provides a comprehensive analysis of the global Cerebrovascular Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cerebrovascular Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cerebrovascular Disease market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cerebrovascular Disease and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cerebrovascular Disease.
The global Cerebrovascular Disease market size is projected to grow from US$ million in 2024 to US$ million in 2031; it is expected to grow at a CAGR of % from 2025 to 2031.
According to Centers for Disease Control and Prevention, cerebrovascular disease is the fourth most common cause of death in the U.S. Following North America, European countries are also expected to show steady growth in the market. In the next few years, Asia-Pacific would show remarkable growth in the cerebrovascular disease market as it is developing at a very rapid pace. The factors which would fuel the growth of the market in Asia Pacific are increasing awareness about cerebrovascular disease, certain family history related to the disease and rapidly developing technologically advanced treatments.
This report presents a comprehensive overview, market shares, and growth opportunities of Cerebrovascular Disease market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Carotid Endarterectomy
Carotid Angioplasty Or Carotid Artery Stenting
Drug Medication (Aspirin, Ticlopidine, And Sulfinpyrazone)
Segmentation by application
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Hospitals & Diagnostic Centers
Contract Research Organizations
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Johnson & Johnson
Amgen
GlaxoSmithKline
Sanofi-Aventis
Merck
Sangamo BioSciences
Aldagen
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Cerebrovascular Disease Market Size 2020-2031
2.1.2 Cerebrovascular Disease Market Size CAGR by Region 2020 VS 2024 VS 2031
2.2 Cerebrovascular Disease Segment by Type
2.2.1 Carotid Endarterectomy
2.2.2 Carotid Angioplasty Or Carotid Artery Stenting
2.2.3 Drug Medication (Aspirin, Ticlopidine, And Sulfinpyrazone)
2.3 Cerebrovascular Disease Market Size by Type
2.3.1 Cerebrovascular Disease Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Cerebrovascular Disease Market Size Market Share by Type (2020-2025)
2.4 Cerebrovascular Disease Segment by Application
2.4.1 Academic & Research Institutes
2.4.2 Pharmaceutical & Biotechnology Companies
2.4.3 Hospitals & Diagnostic Centers
2.4.4 Contract Research Organizations
2.4.5 Others
2.5 Cerebrovascular Disease Market Size by Application
2.5.1 Cerebrovascular Disease Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Cerebrovascular Disease Market Size Market Share by Application (2020-2025)
3 Cerebrovascular Disease Market Size by Player
3.1 Cerebrovascular Disease Market Size Market Share by Players
3.1.1 Global Cerebrovascular Disease Revenue by Players (2020-2025)
3.1.2 Global Cerebrovascular Disease Revenue Market Share by Players (2020-2025)
3.2 Global Cerebrovascular Disease Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Cerebrovascular Disease by Regions
4.1 Cerebrovascular Disease Market Size by Regions (2020-2025)
4.2 Americas Cerebrovascular Disease Market Size Growth (2020-2025)
4.3 APAC Cerebrovascular Disease Market Size Growth (2020-2025)
4.4 Europe Cerebrovascular Disease Market Size Growth (2020-2025)
4.5 Middle East & Africa Cerebrovascular Disease Market Size Growth (2020-2025)
5 Americas
5.1 Americas Cerebrovascular Disease Market Size by Country (2020-2025)
5.2 Americas Cerebrovascular Disease Market Size by Type (2020-2025)
5.3 Americas Cerebrovascular Disease Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cerebrovascular Disease Market Size by Region (2020-2025)
6.2 APAC Cerebrovascular Disease Market Size by Type (2020-2025)
6.3 APAC Cerebrovascular Disease Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Cerebrovascular Disease by Country (2020-2025)
7.2 Europe Cerebrovascular Disease Market Size by Type (2020-2025)
7.3 Europe Cerebrovascular Disease Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cerebrovascular Disease by Region (2020-2025)
8.2 Middle East & Africa Cerebrovascular Disease Market Size by Type (2020-2025)
8.3 Middle East & Africa Cerebrovascular Disease Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Cerebrovascular Disease Market Forecast
10.1 Global Cerebrovascular Disease Forecast by Regions (2026-2031)
10.1.1 Global Cerebrovascular Disease Forecast by Regions (2026-2031)
10.1.2 Americas Cerebrovascular Disease Forecast
10.1.3 APAC Cerebrovascular Disease Forecast
10.1.4 Europe Cerebrovascular Disease Forecast
10.1.5 Middle East & Africa Cerebrovascular Disease Forecast
10.2 Americas Cerebrovascular Disease Forecast by Country (2026-2031)
10.2.1 United States Cerebrovascular Disease Market Forecast
10.2.2 Canada Cerebrovascular Disease Market Forecast
10.2.3 Mexico Cerebrovascular Disease Market Forecast
10.2.4 Brazil Cerebrovascular Disease Market Forecast
10.3 APAC Cerebrovascular Disease Forecast by Region (2026-2031)
10.3.1 China Cerebrovascular Disease Market Forecast
10.3.2 Japan Cerebrovascular Disease Market Forecast
10.3.3 Korea Cerebrovascular Disease Market Forecast
10.3.4 Southeast Asia Cerebrovascular Disease Market Forecast
10.3.5 India Cerebrovascular Disease Market Forecast
10.3.6 Australia Cerebrovascular Disease Market Forecast
10.4 Europe Cerebrovascular Disease Forecast by Country (2026-2031)
10.4.1 Germany Cerebrovascular Disease Market Forecast
10.4.2 France Cerebrovascular Disease Market Forecast
10.4.3 UK Cerebrovascular Disease Market Forecast
10.4.4 Italy Cerebrovascular Disease Market Forecast
10.4.5 Russia Cerebrovascular Disease Market Forecast
10.5 Middle East & Africa Cerebrovascular Disease Forecast by Region (2026-2031)
10.5.1 Egypt Cerebrovascular Disease Market Forecast
10.5.2 South Africa Cerebrovascular Disease Market Forecast
10.5.3 Israel Cerebrovascular Disease Market Forecast
10.5.4 Turkey Cerebrovascular Disease Market Forecast
10.5.5 GCC Countries Cerebrovascular Disease Market Forecast
10.6 Global Cerebrovascular Disease Forecast by Type (2026-2031)
10.7 Global Cerebrovascular Disease Forecast by Application (2026-2031)
11 Key Players Analysis
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Information
11.1.2 Johnson & Johnson Cerebrovascular Disease Product Offered
11.1.3 Johnson & Johnson Cerebrovascular Disease Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Johnson & Johnson Main Business Overview
11.1.5 Johnson & Johnson Latest Developments
11.2 Amgen
11.2.1 Amgen Company Information
11.2.2 Amgen Cerebrovascular Disease Product Offered
11.2.3 Amgen Cerebrovascular Disease Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Amgen Main Business Overview
11.2.5 Amgen Latest Developments
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Information
11.3.2 GlaxoSmithKline Cerebrovascular Disease Product Offered
11.3.3 GlaxoSmithKline Cerebrovascular Disease Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 GlaxoSmithKline Main Business Overview
11.3.5 GlaxoSmithKline Latest Developments
11.4 Sanofi-Aventis
11.4.1 Sanofi-Aventis Company Information
11.4.2 Sanofi-Aventis Cerebrovascular Disease Product Offered
11.4.3 Sanofi-Aventis Cerebrovascular Disease Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Sanofi-Aventis Main Business Overview
11.4.5 Sanofi-Aventis Latest Developments
11.5 Merck
11.5.1 Merck Company Information
11.5.2 Merck Cerebrovascular Disease Product Offered
11.5.3 Merck Cerebrovascular Disease Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Merck Main Business Overview
11.5.5 Merck Latest Developments
11.6 Sangamo BioSciences
11.6.1 Sangamo BioSciences Company Information
11.6.2 Sangamo BioSciences Cerebrovascular Disease Product Offered
11.6.3 Sangamo BioSciences Cerebrovascular Disease Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Sangamo BioSciences Main Business Overview
11.6.5 Sangamo BioSciences Latest Developments
11.7 Aldagen
11.7.1 Aldagen Company Information
11.7.2 Aldagen Cerebrovascular Disease Product Offered
11.7.3 Aldagen Cerebrovascular Disease Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Aldagen Main Business Overview
11.7.5 Aldagen Latest Developments
12 Research Findings and Conclusion